{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:31:14Z","timestamp":1725409874314},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"DOI":"10.7759\/cureus.68481","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:03:52Z","timestamp":1725321832000},"source":"Crossref","is-referenced-by-count":0,"title":["A Meta-Analysis of Randomized Controlled Trials Comparing the Efficacy and Safety of Hydrophilic Versus Lipophilic Statins in Acute Coronary Syndrome Patients"],"prefix":"10.7759","author":[{"given":"Rofayda  M","family":"Mohamad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiah A","family":"Almoayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aseel Ahmed  A","family":"Alanmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Abdullah S","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed Hassan S","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandar Eid H","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahal Hassan A","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed  Khalid A","family":"Baqays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuruq Talea B","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema Jasim M","family":"Meftah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman Ayed  R","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleha Mohammed H","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maali Hamdan S","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent E","year":"2021","unstructured":"Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins?. Front Cardiovasc Med. 2021, 8:687585. 10.3389\/fcvm.2021.687585","journal-title":"Front Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 73:e285-350. 10.1016\/j.jacc.2018.11.003","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.11.004","article-title":"Pleiotropic effects of statin therapy: molecular mechanisms and clinical results","volume":"14","author":"Wang CY","year":"2008","unstructured":"Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008, 14:37-44. 10.1016\/j.molmed.2007.11.004","journal-title":"Trends Mol Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0499-9","article-title":"Statin effects on atherosclerotic plaques: regression or healing?","volume":"13","author":"Bittencourt MS","year":"2015","unstructured":"Bittencourt MS, Cerci RJ. Statin effects on atherosclerotic plaques: regression or healing?. BMC Med. 2015, 13:260. 10.1186\/s12916-015-0499-9","journal-title":"BMC Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63438-2.00011-0","article-title":"Cholesterol synthesis","author":"Brown AJ","year":"2016","unstructured":"Brown AJ, Sharpe LJ. Cholesterol synthesis. Biochemistry of Lipids, Lipoproteins and Membranes (Sixth Edition). Ridgway ND, McLeod RS (ed): Elsevier, Boston; 2016. 327-58. 10.1016\/B978-0-444-63438-2.00011-0"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X13666170426104611","article-title":"The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature","volume":"13","author":"Diamantis E","year":"2017","unstructured":"Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev. 2017, 13:209-16. 10.2174\/1573403X13666170426104611","journal-title":"Curr Cardiol Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2015.10.005","article-title":"Biochemistry of statins","volume":"73","author":"Egom EE","year":"2016","unstructured":"Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016, 73:127-68. 10.1016\/bs.acc.2015.10.005","journal-title":"Adv Clin Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200002000-00012","article-title":"Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs","volume":"35","author":"Satoh K","year":"2000","unstructured":"Satoh K, Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol. 2000, 35:256-62. 10.1097\/00005344-200002000-00012","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1253\/circj.71.1348","article-title":"Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI","volume":"71","author":"Sakamoto T","year":"2007","unstructured":"Sakamoto T, Kojima S, Ogawa H, et al.. Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI. Circ J. 2007, 71:1348-53. 10.1253\/circj.71.1348","journal-title":"Circ J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2010.01.005","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B\/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study","volume":"103","author":"Lablanche JM","year":"2010","unstructured":"Lablanche JM, Leone A, Merkely B, et al.. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B\/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. Arch Cardiovasc Dis. 2010, 103:160-9. 10.1016\/j.acvd.2010.01.005","journal-title":"Arch Cardiovasc Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.12.015","article-title":"Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study)","volume":"109","author":"Pitt B","year":"2012","unstructured":"Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012, 109:1239-46. 10.1016\/j.amjcard.2011.12.015","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.03.003","article-title":"Hydrophilic vs lipophilic statins in coronary artery disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Byty\u00e7i I","year":"2017","unstructured":"Byty\u00e7i I, Bajraktari G, Bhatt DL, Morgan CJ, Ahmed A, Aronow WS, Banach M. Hydrophilic vs lipophilic statins in coronary artery disease: a meta-analysis of randomized controlled trials. J Clin Lipidol. 2017, 11:624-37. 10.1016\/j.jacl.2017.03.003","journal-title":"J Clin Lipidol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2020.834","article-title":"Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial","volume":"108","author":"Clark JM","year":"2020","unstructured":"Clark JM, Sanders S, Carter M, et al.. Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial. J Med Libr Assoc. 2020, 108:195-207. 10.5195\/jmla.2020.834","journal-title":"J Med Libr Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","unstructured":"The R Project for Statistical Computing. (2024). https.\/\/www.r-project.org."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi S","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019, 22:153-60. 10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"ref19","article-title":"Doing Meta-Analysis With R: A Hands-On Guide","author":"Harrer M","year":"2022","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing Meta-Analysis With R: A Hands-On Guide. CRC Press, Boca Raton; 2022."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon CP","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-504. 10.1056\/NEJMoa040583","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/HJR.0b013e3283316ce8","article-title":"A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial","volume":"16","author":"Hall AS","year":"2009","unstructured":"Hall AS, Jackson BM, Farrin AJ, et al.. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial. Eur J Cardiovasc Prev Rehabil. 2009, 16:712-21. 10.1097\/HJR.0b013e3283316ce8","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.10.005","article-title":"Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial","volume":"54","author":"Murphy SA","year":"2009","unstructured":"Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009, 54:2358-62. 10.1016\/j.jacc.2009.10.005","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-0877","article-title":"Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction - ALPS-AMI study","volume":"79","author":"Izawa A","year":"2015","unstructured":"Izawa A, Kashima Y, Miura T, et al.. Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction - ALPS-AMI study. Circ J. 2015, 79:161-8. 10.1253\/circj.CJ-14-0877","journal-title":"Circ J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.21651","article-title":"Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI)","volume":"81","author":"He W","year":"2020","unstructured":"He W, Cao M, Li Z. Effects of different doses of atorvastatin, rosuvastatin, and simvastatin on elderly patients with ST-elevation acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI). Drug Dev Res. 2020, 81:551-6. 10.1002\/ddr.21651","journal-title":"Drug Dev Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000506857","article-title":"A prospective, randomized, open-label trial of atorvastatin versus rosuvastatin in the prevention of contrast-induced acute kidney injury, worsened renal function at 30 days, and clinical events after acute coronary angiography: the PRATO-ACS-2 study","volume":"10","author":"Toso A","year":"2020","unstructured":"Toso A, Leoncini M, Maioli M, Tropeano F, Villani S, Bellandi F. A prospective, randomized, open-label trial of atorvastatin versus rosuvastatin in the prevention of contrast-induced acute kidney injury, worsened renal function at 30 days, and clinical events after acute coronary angiography: the PRATO-ACS-2 study. Cardiorenal Med. 2020, 10:288-301. 10.1159\/000506857","journal-title":"Cardiorenal Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee YJ","year":"2023","unstructured":"Lee YJ, Hong SJ, Kang WC, et al.. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023, 383:e075837. 10.1136\/bmj-2023-075837","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(89)92773-3","article-title":"Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo","volume":"158","author":"Germershausen JI","year":"1989","unstructured":"Germershausen JI, Hunt VM, Bostedor RG. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun. 1989, 158:667-75. 10.1016\/0006-291x(89)92773-3","journal-title":"Biochem Biophys Res Commun"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/polym13050711","article-title":"Polymers and nanoparticles for statin delivery: current use and future perspectives in cardiovascular disease","volume":"13","author":"Nenna A","year":"2021","unstructured":"Nenna A, Nappi F, Larobina D, Verghi E, Chello M, Ambrosio L. Polymers and nanoparticles for statin delivery: current use and future perspectives in cardiovascular disease. Polymers (Basel). 2021, 13:10.3390\/polym13050711","journal-title":"Polymers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-201X.2004.01392.x","article-title":"Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia\/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level","volume":"183","author":"Bulhak AA","year":"2005","unstructured":"Bulhak AA, Gourine AV, Gonon AT, Sj\u00f6quist PO, Valen G, Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia\/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand. 2005, 183:151-9. 10.1111\/j.1365-201X.2004.01392.x","journal-title":"Acta Physiol Scand"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200303000-00017","article-title":"Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase","volume":"41","author":"Wolfrum S","year":"2003","unstructured":"Wolfrum S, Grimm M, Heidbreder M, Dendorfer A, Katus HA, Liao JK, Richardt G. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003, 41:474-80. 10.1097\/00005344-200303000-00017","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.05.022","article-title":"Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials","volume":"241","author":"Sahebkar A","year":"2015","unstructured":"Sahebkar A, Kotani K, Serban C, et al.. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015, 241:433-42. 10.1016\/j.atherosclerosis.2015.05.022","journal-title":"Atherosclerosis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/291580-a-meta-analysis-of-randomized-controlled-trials-comparing-the-efficacy-and-safety-of-hydrophilic-versus-lipophilic-statins-in-acute-coronary-syndrome-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:03:56Z","timestamp":1725321836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/291580-a-meta-analysis-of-randomized-controlled-trials-comparing-the-efficacy-and-safety-of-hydrophilic-versus-lipophilic-statins-in-acute-coronary-syndrome-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.68481","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}